LOGIN  |  REGISTER

Ardent Health Partners Updates Name to Ardent Health

May 23, 2025 | Last Trade: US$12.69 0.16 1.28

BRENTWOOD, Tenn. / May 23, 2025 / Business Wire / Ardent Health Partners, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that its board of directors voted to change the Company’s name to Ardent Health, Inc., effective June 3, 2025. The updated name aligns the Company’s legal name with its practice of referring to the organization as “Ardent Health” in its communications, ensuring a clear and consistent brand identity.

The name change will have no impact on Ardent Health’s trading symbol on the New York Stock Exchange, its CUSIP number, nor the rights of its stockholders. Ardent Health anticipates that its common stock will begin trading under its updated name on June 3, 2025.

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.

Astria Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page